Skip to content

Bioalmanac

Semax

ACTH (4-10) analogue · Met-Glu-His-Phe-Pro-Gly-Pro

Approved for another indication

Status reviewed 12 Aug 2026

A seven-amino-acid peptide developed in Russia and approved there for stroke and cognitive indications. It holds no approval elsewhere and is used nasally rather than injected.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Nasal solutions are entered repeatedly, so bacteriostatic water rather than sterile water matters here.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly described nasal dose300–600 mcgOnce or twice daily, split between nostrilsCommunity practice

When to stop

  • Persistent nasal pain, bleeding or crusting.
  • Any allergic response: rash, facial swelling or difficulty breathing. Seek urgent care.
  • Marked anxiety, agitation or insomnia that appears after starting.
  • Any new neurological symptom — headache pattern change, visual disturbance, weakness.

Approved and clinically used in Russia, where it appears on the essential medicines list. Not approved in the United States, the EU or the UK, and material sold in those markets is an unapproved substance with no manufacturing standard behind it.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/semax

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.